Scholarlink

<p>Real-world impact of device-aided therapy on quality of life (QoL) in people with Parkinson’s remains unknown. This large, retrospective, observational study assessed QoL in people transitioning to device-aided therapy (deep brain stimulation or carbidopa-levodopa enteral suspension) vs. those continuing oral medications. Cohorts were matched based on clinical/demographic characteristics and device-aided therapy eligibility. Primary and secondary outcomes included change from baseline (CFB) to month 12 in 39-item Parkinson’s Disease Questionnaire (PDQ-39) and Unified Parkinson’s Disease Rating Scale (UPDRS) scores, respectively. Of 608 people (oral therapy [<i>n</i> = 295]; device-aided therapy [<i>n</i> = 313]), most were male, White, and aged ≥ 60 years. Positive CFB to month 12 in PDQ-39 was significantly greater for device-aided therapy vs. oral therapy (–5.0 [95% CI, –5.9 to –4.2] vs. 0.9 [0.3–1.5]; <i>p</i> &lt; 0.001). UPDRS II-IV scores improved for the device-aided therapy group. People transitioning to device-aided therapy experienced clinically meaningful QoL improvements.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Parkinson’s disease quality of life at 12 months comparing invasive device-aided therapy with oral treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月11日

查看全文
  • Adolfo Ramirez-Zamora,
  • Michael S. Okun,
  • Pavnit Kukreja,
  • Wei Hu

摘要

Real-world impact of device-aided therapy on quality of life (QoL) in people with Parkinson’s remains unknown. This large, retrospective, observational study assessed QoL in people transitioning to device-aided therapy (deep brain stimulation or carbidopa-levodopa enteral suspension) vs. those continuing oral medications. Cohorts were matched based on clinical/demographic characteristics and device-aided therapy eligibility. Primary and secondary outcomes included change from baseline (CFB) to month 12 in 39-item Parkinson’s Disease Questionnaire (PDQ-39) and Unified Parkinson’s Disease Rating Scale (UPDRS) scores, respectively. Of 608 people (oral therapy [n = 295]; device-aided therapy [n = 313]), most were male, White, and aged ≥ 60 years. Positive CFB to month 12 in PDQ-39 was significantly greater for device-aided therapy vs. oral therapy (–5.0 [95% CI, –5.9 to –4.2] vs. 0.9 [0.3–1.5]; p < 0.001). UPDRS II-IV scores improved for the device-aided therapy group. People transitioning to device-aided therapy experienced clinically meaningful QoL improvements.